Parkinson's Disease Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The Parkinson’s disease drugs market was valued at USD 5.76 Billion in 2025. It is poised to grow at a CAGR of 3.58% during the forecast period of 2026-2035, and reach USD 8.19 Billion by 2035. The market growth is driven by rising Parkinson’s prevalence, increasing adoption of carbidopa-levodopa and dopamine agonists, expanding geriatric population, and advancements in oral and injectable formulations enhancing patient compliance and therapeutic outcomes.

Key Market Trends and Insights

• Based on drug class, carbidopa/levodopa accounted for over 35% of the market share in the historical period.
• Oral formulations represented approximately 75% of the market by route of administration in the historical period.
• By region, the United States dominated the market, capturing around 41% of market share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 5.76 Billion
• Projected Market Size (2035): USD 8.19 Billion
• CAGR (2026-2035): 3.58%

Parkinson’s Disease Drugs Market Overview

The market is expanding steadily, driven by the increasing prevalence of Parkinson’s, an aging global population, and growing awareness of early diagnosis. Oral formulations dominate, with carbidopa/levodopa remaining the most prescribed therapy. The market growth is supported by innovations in drug delivery, improved patient adherence, and rising adoption of advanced treatment options across developed and emerging regions. The market reached a value of approximately USD 5.76 Billion in 2025.

Parkinson’s Disease Drugs Market Growth Drivers

Regulatory Approvals for Subcutaneous Dopamine Agonists Boosting the Market Expansion

Growing demand for advanced-stage management and increasing regulatory support for innovative delivery technologies are propelling the market. For instance, in February 2025, Supernus Pharmaceuticals received FDA approval for Onapgo, the first subcutaneous continuous infusion dopamine agonist device for advanced Parkinson's disease. This milestone is projected to expand market reach and accelerate infusion-based formulation adoption through the forecast period.

Parkinson’s Disease Drugs Market Trends

Key trends shaping the market include increasing use of MAO-B inhibitors, rising geriatric population, technological advancements, and expanding access to innovative therapies globally.

Advancements in Subcutaneous Levodopa-Based Infusion Approvals Reshaping the Market Landscape

The rising prevalence of advanced-stage Parkinson's and demand for non-surgical symptom control are reshaping the market. Subcutaneous delivery innovations are overcoming oral formulation limitations. For instance, in October 2024, AbbVie received FDA approval for Vyalev, the first 24-hour subcutaneous levodopa-based infusion therapy for motor fluctuations in advanced Parkinson's disease, expected to redefine treatment paradigms and drive market expansion in the forecast period.

Parkinson’s Disease Drugs Market Segmentation

Market Breakup by Drug Class

• MAO-B Inhibitors
• Carbidopa/levodopa
• COMT Inhibitors
• Dopamine Agonists
• Anticholinergics
• Amantadine
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel

Market Breakup by End User

• Hospital
• Specialty Clinics
• Homecare Settings
• Academic and Healthcare Settings
• Others

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Parkinson’s Disease Drugs Market Share

Oral Expected to Lead the Market Segment by Route Of Administration

Oral dominated the market segment by route of administration during the historical period, holding about 75% of the total market. These formulations remain preferred due to ease of use, consistent dosing, and improved patient adherence. Among therapies, carbidopa/levodopa continues to be the backbone of treatment, driving demand and supporting steady growth across global healthcare settings.

Parkinson’s Disease Drugs Market Analysis by Region

The United States led the market geographically during the historical period, capturing approximately 42% of the market. The market growth is supported by advanced healthcare infrastructure, early diagnosis initiatives, and high adoption of innovative therapies. In particular, dopamine agonist treatments are increasingly utilized to manage motor symptoms, reinforcing the region’s dominance in market share.

Leading Players in the Parkinson’s Disease Drugs Market

The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Medtronic plc

Established in 1949, Medtronic plc is headquartered in Dublin, Ireland. In Parkinson’s Disease, it is recognized for deep brain stimulation systems that provide precise neuromodulation for motor symptom control. Medtronic also supports programmable implantable devices and patient monitoring platforms, aiming to enhance therapeutic outcomes and advance reserach in Parkinson’s disease-modifying management.

Pfizer, Inc.

Founded in 1849 and headquartered in New York, USA, Pfizer, Inc. develops therapies for neurological disorders, including Parkinson’s disease. The company’s portfolio features dopamine agonist medications that help manage motor symptoms. Pfizer continues research on disease-modifying therapies and adjunctive treatments to improve patient quality of life and reduce motor complications.

AbbVie Inc.

AbbVie Inc., founded in 2013 and based in North Chicago, USA, develops therapies addressing neurodegenerative conditions. In Parkinson’s Disease, AbbVie focuses on COMT inhibitors and dyskinesia management solutions. The company actively invests in clinical trials for novel disease-modifying therapies while providing supportive care options to enhance patient motor function and daily living activities.

GlaxoSmithKline plc.

Headquartered in London, UK, and founded in 2000 through a merger, GlaxoSmithKline plc. offers a range of Parkinson’s Disease therapies. Their portfolio includes MAO-B inhibitors that support symptom management and adjunctive care. GSK emphasizes research on innovative compounds targeting disease progression, as well as improving patient adherence and long-term treatment outcomes.

Other key players in the market are Viatris, Teva Pharmaceutical Industries Ltd, H. Lundbeck A/S, Merck & Co., Inc., Supernus Pharmaceuticals, Inc., and Novartis AG.

Key Questions Answered in the Parkinson’s Disease Drugs Market

• What was the Parkinson’s disease drugs market value in 2025?
• What is the Parkinson’s disease drugs market forecast outlook for 2026-2035?
• What major factors aid the demand for Parkinson’s disease drugs market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major Parkinson’s disease drugs market trends?
• Which drug class is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the Parkinson’s disease drugs market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?